Bu tez, sepsis hastalarında IVIG verme zamanı ile ilgili devam eden gözlemsel çalışmanın ilk sonuçlarının paylaşıldığı veriler içermektedir. Literatürde bu konuda yayınlanmış sadece iki çalışma vardır.
Çalışmaya 130 hasta alındı. İnotrop kullanan hasta grubunda mortalite oranı istatiksel olarak daha yüksek saptandı. Ölen grupta SKB, DKB ve albumin değerleri yaşayan grupa göre istatiksel anlamlı düşük saptandı. Yaşayan grupta CRP (Δ CRP) ve MPV (Δ MPV) değişimlerinde istatiksel anlamlı düşme, albumin (Δ Albumin) ve PLT (Δ PLT) değişimlerinde ise artma saptandı. Grup 1 (IVIG<24 saat) ve Grup 2 (IVIG>24 saat) arasında mortalite açısından anlamlı faklılık saptanmadı. Bunun nedeni hasta sayısının az olması olabilir. Grup 1’de (IVIG<24 saat) albumin değişiminde (Δ Albumin) istatiksel anlamlı artış saptandı.
Her ne kadar az hasta popülasyonunda elde ettiğimiz veriler sunulmuş olsa da, Sepsis ve septik şokta erken IVIG tedavisi ile mortalitenin azalacağını düşünmekteyiz. Mortalite ön görücüsü olarak saptadığımız albumin değişiminin, erken grupta anlamlı daha iyi çıkması da bu olasılığı desteklemektedir. Süregelen dönemde, artan hasta sayısı ile daha sağlıklı veriler elde edeceğimizi düşünmekteyiz.
Sepsis ve septik şok tüm dünyada önemli sağlık sorunu ve ciddi mortalite nedenleridir. Bu yüzden hastalara erken dönemde tanı konulması ve erken tedavi başlanması hayat kurtarıcıdır.
KAYNAKLAR
1. van Vught LA, Klouwenberg PMK, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. 2016;315(14):1469-79.
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. 2017;43(3):304-77.
3. Torio CM, Andrews RM. National inpatient hospital costs: the most expensive conditions by payer, 2011: statistical brief# 160. 2006.
4. Manship L, McMillin R, Brown JJTAS. The influence of sepsis and multisystem and organ failure on mortality in the surgical intensive care unit. 1984;50(2):94-101.
5. Niederman M, Fein AJCicm. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia. A common clinical sequence. 1990;11(4):633-56. 6. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Critical care.
2006;10(2):R42.
7. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care medicine. 2017;43(3):304-77.
8. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. The Lancet infectious diseases. 2013;13(3):260-8.
9. Laupland KB. Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults. Canadian Journal of Infectious Diseases and Medical Microbiology. 2002;13(2):100-6.
10. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M– enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. Journal of critical care. 2005;20(3):239-49.
11. Alejandria M, Lansang M, Dans L, Mantaring J. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Review. 1999.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. 1992;101(6):1644-55.
14. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). Jama. 2016;315(8):801-10.
15. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MRJCcm. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. 2001;29(7):1303-10.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 sccm/esicm/accp/ats/sis international sepsis definitions conference. 2003;29(4):530-8.
17. Ziesmann MT, Marshall JCJSi. Multiple organ dysfunction: the defining syndrome of sepsis. 2018;19(2):184-90.
18. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. 2008;12(6):R158.
19. Wheeler AP, Bernard GR. Treating patients with severe sepsis. New England Journal of Medicine. 1999;340(3):207-14.
20. Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. Bmj. 2016;353:i1585.
21. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Critical care medicine. 2007;35(5):1244-50.
22. Lagu T, Rothberg MB, Shieh M-S, Pekow PS, Steingrub JS, Lindenauer PK. What is the best method for estimating the burden of severe sepsis in the United States? Journal of critical care. 2012;27(4):414. e1-. e9.
23. Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: cardiovascular and immunological aspects. Virulence. 2014;5(1):12-9.
24. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Critical care medicine. 2006;34(1):15-21.
25. Janeway Jr C. Medzhitov R.(2002) Annu. Rev Immunol.20:197-216.
26. Lemaitre B, Nicolas E, Michaut L, Reichhart J-M, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86(6):973-83.
27. Brunn GJ, Platt JL. The etiology of sepsis: turned inside out. Trends in molecular medicine. 2006;12(1):10-6.
29. Akira S, Takeda K. Toll-like receptor signalling. Nature reviews immunology. 2004;4(7):499.
30. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):cm1-cm.
31. Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. Multiplex cytokine profiling in patients with sepsis. Apmis. 2011;119(2):155-63.
32. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. The Journal of clinical investigation. 2011;121(9):3375-83.
33. Gouel-Chéron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G, et al. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PloS one.
2012;7(3):e33095.
34. Chousterman BG, Swirski FK, Weber GF, editors. Cytokine storm and sepsis disease pathogenesis. Seminars in immunopathology; 2017: Springer.
35. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al.
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of internal medicine. 2007;167(15):1655-63.
36. Riedemann NC, Guo R-F, Hollmann TJ, Gao H, Neff TA, Reuben JS, et al. Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis. The FASEB journal. 2004;18(2):370-2.
37. Riedemann NC, Neff TA, Guo R-F, Bernacki KD, Laudes IJ, Sarma JV, et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. The Journal of Immunology. 2003;170(1):503-7.
38. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547-9.
39. Costa VS, Mattana TCC, da Silva MER. Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes research and clinical practice. 2010;88(3):222-6.
40. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine & growth factor reviews. 2010;21(6):413-23. 41. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17- producing T cells. Immunity. 2006;24(2):179-89.
42. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T H-17 cell–mediated pathology. Nature immunology. 2007;8(12):1390.
43. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T H 17 cells. Nature. 2007;448(7152):484. 44. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon‐γ: an overview of signals, mechanisms and functions. Journal of leukocyte biology. 2004;75(2):163-89.
45. Schoenborn JR, Wilson CB. Regulation of interferon‐γ during innate and adaptive immune responses. Advances in immunology. 2007;96:41-101.
46. Romero CR, Herzig DS, Etogo A, Nunez J, Mahmoudizad R, Fang G, et al. The role of interferon‐γ in the pathogenesis of acute intra‐abdominal sepsis. Journal of leukocyte biology. 2010;88(4):725-35.
47. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H. Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. The American journal of surgery. 2001;182(5):491-7. 48. Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S. CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-κB, and MAPKs. The Journal of Immunology. 2010;185(10):6214-25.
49. Robben PM, LaRegina M, Kuziel WA, Sibley LD. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. Journal of Experimental Medicine.
2005;201(11):1761-9.
50. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, Jaeger M, et al. CX 3 CR1-dependent renal macrophage survival promotes Candida control and host survival. The Journal of clinical investigation. 2013;123(12):5035-51.
51. Chousterman BG, Boissonnas A, Poupel L, de Chanville CB, Adam J, Tabibzadeh N, et al. Ly6Chigh monocytes protect against kidney damage during sepsis via a CX3CR1- dependent adhesion mechanism. Journal of the American Society of Nephrology. 2016;27(3):792-803.
52. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nature Reviews Immunology. 2008;8(7):533.
53. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, et al. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 1997;386(6621):194.
54. Dinarello CA, editor Induction of interleukin-1 and interleukin-1 receptor antagonist. Seminars in oncology; 1997.
55. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA. Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram- negative sepsis in rats. Surgery. 1992;112(2):188-94.
negative pneumonia. American journal of respiratory and critical care medicine. 2011;183(10):1380-90.
57. Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nature Reviews Immunology. 2015;15(5):271.
58. Luzina IG, Keegan AD, Heller NM, Rook GA, Shea‐Donohue T, Atamas SP.
Regulation of inflammation by interleukin‐4: a review of “alternatives”. Journal of leukocyte biology. 2012;92(4):753-64.
59. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. The Journal of Immunology. 2008;180(9):5771-7.
60. Opal SM, Depalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-72. 61. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature Reviews Immunology. 2013;13(12):862. 62. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science.
2015;347(6227):1260-5.
63. Bentzer P, Fjell C, Walley KR, Boyd J, Russell JA. Plasma cytokine levels predict response to corticosteroids in septic shock. Intensive care medicine. 2016;42(12):1970-9. 64. Rivers EP, McIntyre L, Morro DC, Rivers KK. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. Cmaj.
2005;173(9):1054-65.
65. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive care medicine. 2004;30(4):536-55.
66. Polat G, Ugan RA, Cadirci E, Halici Z. Sepsis and septic shock: current treatment strategies and new approaches. The Eurasian journal of medicine. 2017;49(1):53.
67. Cronin L, Cook DJ, Carlet J, Heyland DK, King DBM, Lansang MAD, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Critical care medicine. 1995;23(8):1430-9.
68. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. The Lancet. 2004;363(9422):1721-3.
69. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine. 1982;307(20):1225-30.
70. Baumgartner J-D, Mccutchan JA, Van Melle G, Vogt M, Luethy R, Glauser M, et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. The Lancet. 1985;326(8446):59-63.
71. Werdan K. Supplemental immune globulins in sepsis. Clinical chemistry and laboratory medicine. 1999;37(3):341-9.
72. Confference NC. Intravenous immunoglobulin: Prevention and treatment of disease. J Am Med Assoc. 1990;264:3189-93.
73. Norrby-teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scandinavian journal of infectious diseases. 2003;35(9):683-9.
74. Mouthon L, Kaveri S, Spalter S, Lacroix-Desmazes S, Lefranc C, Desai R, et al. Mechanisms of action of intravenous immune globulin in immune‐mediated diseases. Clinical & Experimental Immunology. 1996;104:3-9.
75. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. Journal of Allergy and Clinical Immunology. 1997;100(2):151-7.
76. Di Rosa R, Pietrosanti M, Luzi G, Salemi S, D'Amelio R. Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis? European Journal of Internal Medicine. 2014;25(6):511-6.
77. Haque KN, Zaidi MH, Bahakim H. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. American journal of diseases of children. 1988;142(12):1293-6. 78. Haque K, Remo C, Bahakim H. Comparison of two types of intravenous
immunoglobulins in the treatment of neonatal sepsis. Clinical & Experimental Immunology. 1995;101(2):328-33.
79. Garbett N, Munro C, Cole P. Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin. Clinical and experimental
immunology. 1989;76(1):8.
80. McCabe WR, DeMaria Jr A, Berberich H, Johns MA. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. Journal of Infectious Diseases. 1988;158(2):291-300.
81. Trautmann M, Held T, Susa M, Karajan M, Wulf A, Cross A, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clinical and experimental immunology. 1998;111(1):81.
82. Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R, Gandia F, Gómez-Herreras JI, Gomez-Sanchez E, et al. Defining immunological dysfunction in sepsis: A requisite tool for precision medicine. Journal of Infection. 2016;72(5):525-36.
83. Giamarellos-Bourboulis EJ, Tziolos N, Routsi C, Katsenos C, Tsangaris I, Pneumatikos I, et al. Improving outcomes of severe infections by multidrug-resistant
84. de la Torre MC, Torán P, Serra-Prat M, Palomera E, Güell E, Vendrell E, et al. Serum levels of immunoglobulins and severity of community-acquired pneumonia. BMJ open respiratory research. 2016;3(1):e000152.
85. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Ñamendys-Silva SA, et al., editors. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open forum infectious diseases; 2018: Oxford University Press US.
86. Venet F, Rimmele T, Monneret G. Management of sepsis-induced immunosuppression. Critical care clinics. 2018;34(1):97-106.
87. Berlot G, Vassallo MC, Busetto N, Bianchi M, Zornada F, Rosato I, et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. Journal of critical care. 2012;27(2):167-71.
88. Berlot G, Vassallo MC, Busetto N, Yabar MN, Istrati T, Baronio S, et al. Effects of the timing of administration of IgM-and IgA-enriched intravenous polyclonal
immunoglobulins on the outcome of septic shock patients. Annals of intensive care. 2018;8(1):122.
89. Lee C-C, Chen S-Y, Tsai C-L, Wu S-C, Chiang W-C, Wang J-L, et al. Prognostic value of mortality in emergency department sepsis score, procalcitonin, and C-reactive protein in patients with sepsis at the emergency department. Shock. 2008;29(3):322-7.
90. Kim MH, Ahn JY, Song JE, Choi H, Ann HW, Kim JK, et al. The C-reactive
protein/albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One. 2015;10(7):e0132109. 91. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS One. 2015;10(3):e0119437.
92. Lee K, Hui K, Tan W. Thrombocytopenia in sepsis: a predictor of mortality in the intensive care unit. Singapore medical journal. 1993;34:245-.
93. Mayaud L, Lai PS, Clifford GD, Tarassenko L, Celi LAG, Annane D. Dynamic data during hypotensive episode improves mortality predictions among patients with sepsis and hypotension. Critical care medicine. 2013;41(4):954.